US Patent

US10335366 — Risperidone or paliperidone implant formulation

Formulation · Assigned to Laboratorios Farmaceuticos Rovi SA · Expires 2031-05-31 · 5y remaining

Vulnerability score 44/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an injectable implant formulation that releases risperidone or paliperidone for at least 4 weeks.

USPTO Abstract

The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.

Drugs covered by this patent

Patent Metadata

Patent number
US10335366
Jurisdiction
US
Classification
Formulation
Expires
2031-05-31
Drug substance claim
No
Drug product claim
Yes
Assignee
Laboratorios Farmaceuticos Rovi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.